PROCTOLOG

Company name

Pfizer Inc

E-mail address of the competent person responsible for the Safety Data Sheet

pfizer-MSDS@pfizer.com

SECTION 2: Hazards identification

Appearance: Suppository

Hazard statements

Non-hazardous in accordance with international standards for workplace safety.

Additional information

Short Term: An Occupational Exposure Limit has been established for one or more of the ingredients (see Section 8). Long Term: Based on its pharmacologic properties and findings in animal studies, this compound may cause gastrointestinal system Known Clinical Effects: Adverse effects associated with therapeutic use of trimebutine are infrequent and include skin rash, sleepiness, headache, vomiting, and dizziness . EU Indication of danger: Not classified Australian Hazard Classification Non-Hazardous Substance. Non-Dangerous Goods. (NOHSC): For a more detailed discussion of potential health hazards and toxicity see Section 11. Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.